Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.07
(-1.75%)
SEK 0.07
(-1.75%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 174.55 Million SEK | -6.01% |
| 2022 | 185.71 Million SEK | 535.98% |
| 2021 | 29.2 Million SEK | -48.83% |
| 2020 | 57.06 Million SEK | 9.31% |
| 2019 | 52.2 Million SEK | 4.76% |
| 2018 | 49.83 Million SEK | -8.37% |
| 2017 | 54.38 Million SEK | -28.77% |
| 2016 | 76.35 Million SEK | 37.27% |
| 2015 | 55.62 Million SEK | 412.1% |
| 2014 | 10.86 Million SEK | 71.52% |
| 2013 | 6.33 Million SEK | -5.68% |
| 2012 | 6.71 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 165.69 Million SEK | -3.11% |
| 2024 Q1 | 171.01 Million SEK | -2.03% |
| 2023 Q4 | 174.55 Million SEK | -11.37% |
| 2023 Q3 | 196.95 Million SEK | 5.22% |
| 2023 Q1 | 183.64 Million SEK | -1.12% |
| 2023 Q2 | 187.17 Million SEK | 1.93% |
| 2023 FY | 174.55 Million SEK | -6.01% |
| 2022 FY | 185.71 Million SEK | 535.98% |
| 2022 Q4 | 185.71 Million SEK | -0.51% |
| 2022 Q3 | 186.66 Million SEK | 338.48% |
| 2022 Q2 | 42.57 Million SEK | 52.92% |
| 2022 Q1 | 27.83 Million SEK | -4.67% |
| 2021 Q2 | 42.06 Million SEK | -12.91% |
| 2021 Q3 | 34.4 Million SEK | -18.22% |
| 2021 FY | 29.2 Million SEK | -48.83% |
| 2021 Q1 | 48.3 Million SEK | -15.36% |
| 2021 Q4 | 29.2 Million SEK | -15.12% |
| 2020 Q3 | 51.54 Million SEK | 17.04% |
| 2020 Q2 | 44.04 Million SEK | -2.05% |
| 2020 FY | 57.06 Million SEK | 9.31% |
| 2020 Q4 | 57.06 Million SEK | 10.7% |
| 2020 Q1 | 44.96 Million SEK | -13.87% |
| 2019 Q3 | 45.88 Million SEK | -1.49% |
| 2019 FY | 52.2 Million SEK | 4.76% |
| 2019 Q4 | 52.2 Million SEK | 13.78% |
| 2019 Q2 | 46.57 Million SEK | -4.82% |
| 2019 Q1 | 48.93 Million SEK | -1.81% |
| 2018 Q4 | 49.83 Million SEK | -26.6% |
| 2018 FY | 49.83 Million SEK | -8.37% |
| 2018 Q1 | 49.42 Million SEK | -9.13% |
| 2018 Q2 | 49.78 Million SEK | 0.73% |
| 2018 Q3 | 67.89 Million SEK | 36.39% |
| 2017 Q4 | 54.38 Million SEK | -8.07% |
| 2017 FY | 54.38 Million SEK | -28.77% |
| 2017 Q1 | 71.07 Million SEK | -6.91% |
| 2017 Q2 | 65.61 Million SEK | -7.69% |
| 2017 Q3 | 59.16 Million SEK | -9.83% |
| 2016 Q2 | 90.04 Million SEK | 73.76% |
| 2016 FY | 76.35 Million SEK | 37.27% |
| 2016 Q1 | 51.82 Million SEK | -6.84% |
| 2016 Q4 | 76.35 Million SEK | -12.53% |
| 2016 Q3 | 87.29 Million SEK | -3.05% |
| 2015 Q4 | 55.62 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | 55.62 Million SEK | 412.1% |
| 2014 FY | 10.86 Million SEK | 71.52% |
| 2013 FY | 6.33 Million SEK | -5.68% |
| 2012 FY | 6.71 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -47.363% |
| Ziccum AB (publ) | 14.97 Million SEK | -1065.856% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -770.975% |
| BioArctic AB (publ) | 1.18 Billion SEK | 85.283% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -179.834% |
| Mendus AB (publ) | 755.95 Million SEK | 76.91% |
| Genovis AB (publ.) | 288.85 Million SEK | 39.571% |
| Intervacc AB (publ) | 259.61 Million SEK | 32.764% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -316.006% |
| Active Biotech AB (publ) | 44 Million SEK | -296.709% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 37.379% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -180.847% |
| Aptahem AB (publ) | 63.02 Million SEK | -176.957% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 64.826% |
| Kancera AB (publ) | 65.64 Million SEK | -165.911% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 50.317% |
| Fluicell AB (publ) | 9.34 Million SEK | -1768.865% |
| Saniona AB (publ) | 64.14 Million SEK | -172.129% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -419.469% |
| Biovica International AB (publ) | 131.4 Million SEK | -32.832% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -229.437% |
| AcouSort AB (publ) | 34.51 Million SEK | -405.757% |
| Xintela AB (publ) | 18.39 Million SEK | -848.91% |
| Abliva AB (publ) | 87.49 Million SEK | -99.49% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 77.039% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 86.129% |
| OncoZenge AB (publ) | 20.34 Million SEK | -758.171% |
| Amniotics AB (publ) | 26.08 Million SEK | -569.141% |
| 2cureX AB (publ) | 16.62 Million SEK | -949.937% |
| CombiGene AB (publ) | 120.61 Million SEK | -44.722% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -2772.338% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 90.816% |
| Camurus AB (publ) | 1.9 Billion SEK | 90.851% |
| Corline Biomedical AB | 100.1 Million SEK | -74.369% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 1.45% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -24.151% |
| I-Tech AB | 152.44 Million SEK | -14.503% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 82.854% |
| Cyxone AB (publ) | 43.65 Million SEK | -299.844% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -121.817% |
| Biosergen AB | 7.2 Million SEK | -2323.997% |
| Cantargia AB (publ) | 223.71 Million SEK | 21.975% |
| NextCell Pharma AB | 81.28 Million SEK | -114.733% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 77.191% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -478.503% |
| Nanologica AB (publ) | 77.42 Million SEK | -125.435% |
| SynAct Pharma AB | 228.01 Million SEK | 23.448% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -552.214% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -704.281% |
| LIDDS AB (publ) | 17.65 Million SEK | -888.683% |
| Lipum AB (publ) | 12.11 Million SEK | -1341.387% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 87.534% |
| Alzinova AB (publ) | 123.18 Million SEK | -41.694% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 26.775% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1964.483% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -104.808% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -1073.932% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 19.575% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 73.29% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -100.469% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -512.291% |